Table I.
Group | Parameter | Mean | Variability (%) |
---|---|---|---|
Placebo | Rate of progression (slope) | 0.16 | 50 |
Symptomatic effect | 0.8 | 50 | |
Rate constant for time to attain maximum symptomatic effect | 0.693 | 50 | |
Baseline UPDRS | 25 | 50 | |
Drug | Rate of progression (slope) | 0.16 | 50 |
Symptomatic effect | 2 | 50 | |
Rate constant for time to attain maximum symptomatic effect | 0.693 | 50 | |
Baseline UPDRS | 25 | 50 |
Units for rate of progression (slope)—per week; symptomatic effect—UPDRS; rate constant for time to attain maximum symptomatic effect (ke0)—per week
UPDRS Unified Parkinson’s Disease Rating Scale